We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: neuroimmunology
MedXY News
EnglishTag

neuroimmunology

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Five-Year Ublituximab Treatment Shows Sustained Benefits in Relapsing Multiple Sclerosis: ULTIMATE Extension Study
Allergy & Immunologyclinical trialDisease-Modifying Therapy

Five-Year Ublituximab Treatment Shows Sustained Benefits in Relapsing Multiple Sclerosis: ULTIMATE Extension Study

By MedXY|Apr 22, 2026

Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c

Age at Onset and Clinical Trajectory in AQP4-IgG NMOSD: Decoupling Relapse Risk from Disability Accrual
Clinical UpdatesDisease Progressionneuroimmunology

Age at Onset and Clinical Trajectory in AQP4-IgG NMOSD: Decoupling Relapse Risk from Disability Accrual

By MedXY|Mar 6, 2026

This review analyzes how age at onset influences NMOSD, revealing that while relapse risk remains constant across age groups, older onset significantly accelerates disability progression, necessitating early high-efficacy therapy.

Long-Term Ublituximab Therapy in Multiple Sclerosis: Five-Year Results from the ULTIMATE I and II Extension Study Validate Early High-Efficacy Intervention
NeurologyB-cell Depletionmultiple sclerosis

Long-Term Ublituximab Therapy in Multiple Sclerosis: Five-Year Results from the ULTIMATE I and II Extension Study Validate Early High-Efficacy Intervention

By MedXY|Feb 20, 2026

Five-year data from the ULTIMATE I and II open-label extension demonstrate that ublituximab maintains exceptionally low relapse rates and slows disability progression in relapsing multiple sclerosis, emphasizing the clinical superiority of

NEOS2 Score: A Precision Tool for Predicting Treatment Response and Three-Year Functional Recovery in Anti-NMDAR Encephalitis
Neurologyneuroimmunology

NEOS2 Score: A Precision Tool for Predicting Treatment Response and Three-Year Functional Recovery in Anti-NMDAR Encephalitis

By MedXY|Jan 28, 2026

The international NEOS2 study validates a refined clinical score using five baseline variables to accurately predict short-term immunotherapy response, one-year functional status, and three-year return to work or school in patients with ant

Refining Prognosis in Anti-NMDAR Encephalitis: The NEOS2 Score Predicts Short- and Long-Term Recovery
NeurologyClinical Prediction Modelsneuroimmunology

Refining Prognosis in Anti-NMDAR Encephalitis: The NEOS2 Score Predicts Short- and Long-Term Recovery

By MedXY|Jan 23, 2026

The NEOS2 score, an updated clinical tool, accurately predicts treatment response, one-year functional status, and three-year work/school resumption in anti-NMDAR encephalitis patients, offering clinicians a robust framework for early treat

Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial
NeurologyChất ức chế BTKfenebrutinib

Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial

By MedXY|Dec 23, 2025

The Phase 2 FENopta trial demonstrates that fenebrutinib, a highly selective, reversible BTK inhibitor, significantly reduces MRI disease activity by 69% in relapsing multiple sclerosis while maintaining a favorable safety profile over 48 w

How Cancer Turns Nerves Against Immunity — and a New Strategy That Could Both Relieve Pain and Boost Immunotherapy
Hematology-Oncologyimmunotherapyneuroimmunology

How Cancer Turns Nerves Against Immunity — and a New Strategy That Could Both Relieve Pain and Boost Immunotherapy

By MedXY|Nov 25, 2025

A Cell study shows head and neck cancers hijack a nerve→lymph node circuit (ATF4→SLIT2→sensory neurons→CGRP) to suppress immunity and cause pain — suggesting nerve-targeting drugs could both ease pain and improve immunotherapy.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities